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OBJECTIVE—Glomerular mesangial expansion and podocyte
loss are important early features of diabetic nephropathy,
whereas tubulointerstitial injury and ﬁbrosis are critical for
progression of diabetic nephropathy to kidney failure. Therefore,
we analyzed the expression of genes in glomeruli and tubuloint-
erstitium in kidney biopsies from diabetic nephropathy patients
to identify pathways that may be activated in humans but not in
murine models of diabetic nephropathy that fail to progress to
glomerulosclerosis, tubulointerstitial ﬁbrosis, and kidney failure.
RESEARCH DESIGN AND METHODS—Kidney biopsies were
obtained from 74 patients (control subjects, early and progres-
sive type 2 diabetic nephropathy). Glomerular and tubulointer-
stitial mRNAs were microarrayed, followed by bioinformatics
analyses. Gene expression changes were conﬁrmed by real-time
RT-PCR and immunohistological staining. Samples from db/db
C57BLKS and streptozotocin-induced DBA/2J mice, commonly
studied murine models of diabetic nephropathy, were analyzed.
RESULTS—In human glomeruli and tubulointerstitial samples,
the Janus kinase (Jak)-signal transducer and activator of tran-
scription (Stat) pathway was highly and signiﬁcantly regulated.
Jak-1, -2, and -3 as well as Stat-1 and -3 were expressed at higher
levels in patients with diabetic nephropathy than in control
subjects. The estimated glomerular ﬁltration rate signiﬁcantly
correlated with tubulointerstitial Jak-1, -2, and -3 and Stat-1
expression (R
2  0.30–0.44). Immunohistochemistry found
strong Jak-2 staining in glomerular and tubulointerstitial com-
partments in diabetic nephropathy compared with control sub-
jects. In contrast, there was little or no increase in expression of
Jak/Stat genes in the db/db C57BLKS or diabetic DBA/2J mice.
CONCLUSIONS—These data suggest a direct relationship be-
tween tubulointerstitial Jak/Stat expression and progression of
kidney failure in patients with type 2 diabetic nephropathy and
distinguish progressive human diabetic nephropathy from non-
progressive murine diabetic nephropathy. Diabetes 58:469–
477, 2009
E
arly clinical diabetic nephropathy is character-
ized by progressive increases in albuminuria
that are associated with the development of
characteristic histopathologic features includ-
ing thickening of the glomerular basement membrane and
mesangial expansion due to accumulation of extracellular
matrix proteins (1). As albuminuria progresses and renal
insufﬁciency ensues, glomerulosclerosis, arteriolar hyali-
nosis, and tubulointerstitial ﬁbrosis develop (2). Mesangial
expansion and the degree of tubulointerstitial ﬁbrosis
correlate inversely with glomerular ﬁltration rate (GFR) in
humans with diabetic kidney disease and appear to be
critical steps in the progression of diabetic nephropathy to
end-stage renal disease (1,3,4). Over 20 years ago, Mauer et
al. (1) established the clear link between mesangial matrix
expansion and progression of diabetic kidney disease by
demonstrating that measures of mesangial expansion
strongly predicted the clinical manifestations of diabetic
nephropathy. The critical role of tubulointerstitial expan-
sion and ﬁbrosis in the progression of diabetic nephropa-
thy has also been recognized for at least two decades (1,5).
Tubulointerstitial changes, including ﬁbrosis, appear to be
critical for ﬁnal progression of diabetic nephropathy to
kidney failure in type 1 diabetic patients and may play an
even more important, though heterogeneous, role in type 2
diabetic patients (6). Despite agreement about these
pathologic predictors, there is no consensus about the
processes that lead to progressive glomerulosclerosis and
tubulointerstitial ﬁbrosis.
While hypothesis-driven studies have led to many in-
sights about the development and progression of diabetic
nephropathy, there is recent interest in using more broad-
based approaches to understanding the pathogenesis of
human renal disease (7–9). Moreover, while current ani-
mal models of diabetic nephropathy replicate well the
early stages of human disease, virtually all fail to develop
the severe glomerulosclerosis, progressive tubulointersti-
tial ﬁbrosis, and gradual decline in GFR that characterize
human diabetic nephropathy (10). Therefore, use of a
broad-based approach with tissues from human patients
with progressive diabetic nephropathy might allow eluci-
dation of pathways that would not be observed in
hypothesis-based studies of animal or cell models (7–9).
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DIABETES, VOL. 58, FEBRUARY 2009 469In this report, we show that a transcriptomic analysis of
glomerular and tubulointerstitial tissues from patients
with early and progressive diabetic nephropathy reveals
regulation of the expression of multiple members of the
Jak/Stat pathway.
We focused on these results because the activation of
Jak/Stat signaling pathways can be implicated in both
tubulointerstitial ﬁbrosis and epithelial to mesenchymal
transition in several conditions, including diabetes, in
animal models (11–13). Similarly, Jak/Stat activation is
reported in rat glomerular cells exposed to high glucose
(14,15) and may be important in the glomerular transform-
ing growth factor- activation and ﬁbronectin accumula-
tion critical for extracellular matrix deposition in early
diabetic nephropathy (15). Moreover, ACE inhibitors and
angiotensin receptor blockers, which prevent the progres-
sion of diabetic nephropathy, also prevent Jak/Stat activa-
tion in glomerular cells from diabetic rats (14). Therefore,
we studied expression and effects of Jak/Stat members in
human and mouse diabetic nephropathy.
RESEARCH DESIGN AND METHODS
Human renal biopsy samples for genome-wide expression proﬁling and
real-time RT-PCR. Gene expression proﬁling of 74 kidney biopsies was
performed essentially as reported by Cohen et al. (16) and Lindenmeyer et al.
(17). For a detailed description, see the online appendix (available at
http://dx.doi.org/10.2337/db08-1328). Clinical data for these patients are pro-
vided in the online appendix Tables 1 and 2.
Microarray target preparation, data processing, analysis, and pathway
mapping. Microarrays from extracted microdissected renal compartment
RNAs were processed following a previously published protocol (18). The
CEL ﬁles were processed by the ChipInspector software (Genomatix Soft-
ware, http://www.genomatix.de). Brieﬂy, and as described in the user manual,
ChipInspector extracted the single probes signiﬁcantly differentially ex-
pressed in Affymetrix GeneChip microarrays (false discovery rate [fdr]  0).
In the designed analysis treatment/control experiment, living donor and
minimal change disease patients were the control group and the early diabetic
nephropathy (Pima Indians) or progressive diabetic nephropathy (European
cohort) subjects were the experiment group. The ChipInspector analysis steps
were as follows: normalization, log2
2 transformation, statistical analysis, and
mapping to transcripts. The resulting lists were uploaded into the Ingenuity
Pathway Analysis software (IPA, www.ingenuity.com). Differential regulation
was displayed in a hierarchical manner with color-coded expression levels. All
the genes of a family were combined and represented by the generic family
name.
Histology and immunohistochemistry. Following the previously described
protocol (19), immunohistochemistry studies were performed from an inde-
pendent cohort of control subjects (histologically veriﬁed unaffected regions
from tumor nephrectomies), type 2 progressive diabetic nephropathy case
subjects, and other kidney disease biopsies (online appendix Table 3). Jak2
staining was performed using a primary monoclonal antibody at 1:100
(AHO1352; Biosource, Camarillo, CA). A biotinylated goat anti-mouse anti-
body (HistoLine; Zymed, Milan, Italy) was used as secondary antibody (1:200).
Morphometric analysis of the progressive diabetic nephropathy patients
included analysis of the numbers of glomeruli that had segmental or global
glomerulosclerosis or were sclerotic. The presence of tubulointerstitial dam-
age was determined by the presence of tubular atrophy, presence of myoﬁ-
broblasts, and/or accumulation of extracellular matrix proteins (online
appendix Table 4).
Animals. Mice were obtained from The Jackson Laboratory (Bar Harbor,
ME). Db/db and db/m mice on a C57BKLS background (BKS.Cg-m
/
Lepr
db/J) became obese around 3–4 weeks and developed hyperglycemia
between 4 and 8 weeks of age. Male 10-week-old DBA/2J mice were allowed
to acclimate to their environment for at least 3 days before injection. Mice
were fasted for 4 h and then given intraperitoneal injections of 40 mg/kg
streptozotocin (STZ) or the vehicle (control mice) daily for 5 consecutive days
as previously reported (10,20). Mice were subcutaneously implanted with
pellets impregnated with bovine insulin (LinBit tablets; LinShin Canada,
Toronto, ON, Canada) at 10 weeks, 15 weeks, and 20 weeks post-STZ. The
administered dose of insulin was 0.1 unit/day. These animals were killed at
24 weeks after completion of STZ injections.
Phenotypic evaluation of the DBA/2J diabetic and control mice was
reported previously (21). Albuminuria was increased threefold, mesangial
matrix was increased 65%, and podocyte number was decreased 30% in the
diabetic DBA/2J mice compared with controls (21). The db/db C57BLKS mice
were not phenotyped in this study. However, this model has been extensively
phenotyped by others in previous studies and has very similar changes of early
diabetic nephropathy (22).
The procedures used in this study were in accordance with the guidelines
of the University of Michigan Committee on the Use and Care of Animals and
conformed to “The Guide for the Care and Use of Laboratory Animals”
(Department of Health, Education, and Welfare, publication no. NIH 86-23).
Veterinary care was provided by the University of Michigan Unit for Labora-
tory Animal Medicine. The University of Michigan is accredited by the
American Association of Laboratory Animal Care.
Mouse kidney samples. Kidney cortex and glomeruli were harvested from
32-week-old diabetic db/db C57BLKS mice and their control db/m littermates
and from STZ-induced diabetic and control DBA/2J mice 24 weeks after STZ
or vehicle injection. Mice were anesthetized by intraperitoneal pentobarbital
(0.06 mg/g body wt). Brieﬂy, blood was ﬂushed from the mice with 0.1 mol/l
PBS (sterile, pH 7.4) via a catheter inserted into the abdominal aorta. A 20-ml
iron oxide bolus (5 mg/ml in 0.9% NaCl) followed. The right kidney was then
removed, minced, and pushed through a 90-m nylon mesh (cat. no. 03-90/49;
Sefar America, Kansas City, MO) into a beaker over a magnet (grade 8), used
to retain the iron-perfused glomeruli, then washed two times with sterile PBS
(pH 7.4). One-ﬁfth of the glomeruli harvested were then stored in RNA Later
(Ambion, Austin-TX) for RNA analysis; the remaining glomeruli were lysed
and stored at 80°C for protein analysis.
Mouse RNA and protein extraction. Total RNA was isolated from the
microdissected tissues using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
following the manufacturer’s instructions. Harvested mouse kidney samples
were lysed in a buffer containing 10 mmol/l Tris-HCl, pH7.4; 150 mmol/l NaCl;
1% Triton X-100; 0.1% SDS; 1 mmol/l Na3VO4; 50 mmol/l NaF; 1 mmol/l
phenylmethylsulphonyl ﬂuoride; and complete protease inhibitor cocktail
(Roche, Indianapolis, IN) and were sonicated and centrifuged 20 min at
15,000g and 4°C. The supernatant was obtained and stored at 80°C until
analyzed.
Human and mouse real-time RT-PCR. Reverse transcription of RNA and
ampliﬁcation was performed as described previously (7) using commercially
available predeveloped TaqMan reagents for Jak-2, Stat-3, and 18S ribosomal
RNA for result normalization (Assay-on-Demand; Applied Biosystems, Darm-
stadt, Germany). Quantiﬁcation of the given templates was performed accord-
ing to the standard curve method for the human samples and the Ct value for
the mouse samples. Serial dilutions of kidney cDNA were included in all PCR
runs and served as standard curve. All measurements were performed in
duplicate. Controls consisting of double distilled H2O were negative in all
runs.
Mesangial cell culture and transfection. Murine mesangial cells obtained
from the American Type Cell Collection (MES-13, cloned from mice trans-
genic for the early region of the SV-40 virus) were grown in low glucose
DMEM (Life Technologies, BRL) containing 5% fetal bovine serum (FBS), 100
units/ml penicillin, and 100 g/ml streptomycin in a humidiﬁed air/5% CO2
atmosphere at 37°C. Nucleofection of mesangial cells was performed accord-
ing to the optimized protocols provided by the manufacturer (Amaxa,
Gaithersburg, MD). Brieﬂy, 1.5  10
6 cells were gently resuspended in 100 l
of Amaxa Nucleofector Solution (cat. no. VCA 1003) and mixed with 1.5 g
Jak-2 prk-5 or vector plasmid (23). Following transfection using the L-29
program on the Amaxa Nucleofector, cells were cultured for 12 h and
incubated in 5.5 mmol/l D-glucose  24.5 mmol/l mannitol or 30 mmol/l
D-glucose serum-free DMEM. Cells were assayed 24 h later for Western
blotting or quantiﬁcation of intracellular reactive oxygen species (ROS).
Transfection efﬁciency as quantiﬁed by nucleofection of the pMAX-GFP
construct (included with the Amaxa kit) was 60% (not shown).
Western blot analysis. Equal amounts of microdissected cortex and glomer-
ular or cultured mesangial cell protein samples were loaded onto 7.5%
SDS-PAGE gels, electrophoresed, and transferred onto nitrocellulose mem-
branes (Schleicher & Schuell, Keene, NH). The blots were then incubated
overnight at 4°C with a monoclonal mouse anti–Jak-2 antibody (AHO1352,
dilutions: 1:1,000 [glomeruli], 1:2000 [cortex]; Biosource), STAT-3 (dilutions:
1:1,000 [glomeruli], 1:2,000 [cortex]; Cell Signaling Technology, Beverly, MA),
phosphor–STAT-3 (tyrosine 705) (dilutions: 1:1,000 [glomeruli], 1:2,000 [cor-
tex]; Cell Signaling Technology); or1ha troom temperature with an
anti–-tubulin antibody (dilution: 1:6,000; Millipore, Lake Placid, NY). Subse-
quently, the blots were washed and incubated for1ha troom temperature
with a horseradish peroxidase–conjugated goat anti-mouse antibody (dilu-
tion: 1:1,000 [glomeruli], SuperSignal West Dura Extended Duration Substrate
kit; Pierce, Rockford, IL; or 1:10000 [cortex], SC-2031; Santa Cruz Biotechnol-
ogy). The peroxidase luminescence intensity was measured using NIH ImageJ
software.
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tored by confocal microscopy using the ﬂuoroprobe carboxymethyl-H2-dichlo-
roﬂuorescein diacetate (CM-H2DCFDA; Molecular Probes, Eugene, OR).
Transfected cells were grown on glass Lab-Tek Chamber Slides (Nunc,
Naperville, IL) in serum-free DMEM for 24 h with either 5.5 mmol/l D-glucose 
24.5 mmol/l mannitol, or 30 mmol/l D-glucose. They were washed with PBS and
incubated in the dark for 30 min in phenol red-free DMEM containing 5 mol/l
CM-H2DCFDA. CM-H2DCFDA passively diffuses into cells, where its acetate
groups are cleaved by intracellular esterases and its thiol-reactive chlorom-
ethyl group reacts with intracellular glutathione and other thiols. Subse-
quent oxidation yields a ﬂuorescent adduct that is trapped inside the cell.
After incubation, images were captured with an Olympus FluoView 500
Laser Scanning Confocal Microscope. Three ﬁelds from each of ﬁve
separate slide wells were assessed for each condition. Fluorescence was
quantiﬁed from 50 randomly chosen cells from each slide well using NIH
ImageJ software.
Statistics. A t test was carried out between the groups of patients. A
Bonferroni correction was performed when multiple samples were being
compared. For protein analyses, a one-way ANOVA followed by Tukey-
Kramer post hoc analysis was performed. P values 	0.05 were considered
statistically signiﬁcant. All data are presented as mean 
 SD or SE, as noted.
RESULTS
Jak/Stat pathway in human diabetic nephropathy.
Pathway mapping from Affymetrix microarray analysis
identiﬁed Jak/Stat signaling as one of the highly regulated
pathways in the glomerular and tubulointerstitial compart-
ments of patients with early and progressive diabetic
nephropathy compared with control subjects (Fig. 1). In
the tubulointerstitial compartment, several Jak/Stat family
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FIG. 1. Jak/Stat canonical pathway in human diabetic nephropathy as assessed by Ingenuity Pathway Analysis software. The Jak/Stat family
members represented include Jak-1, -2, and -3 and Stat-1, -2, -3, -4, -5A, -5B, and -6. The mRNA expression changes for Jak/Stat family members
in early (PIMA Indians, n  22–24) (left panel) and progressive (European, n  7–11) (right panel) human diabetic nephropathy (DN) are
indicated in red for increased expression and green for decreased expression, compared with the corresponding control group (LD  MCD, n 
7–12). 2000–2008 Ingenuity Systems. All rights reserved. LD, living donor; MCD, minimal change disease.
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DIABETES, VOL. 58, FEBRUARY 2009 471members were downregulated in early diabetic nephropa-
thy patients, whereas most were expressed at higher levels
in progressive diabetic nephropathy patients compared
with control subjects (Fig. 1, upper panel). These included
Jak-1, -2, and -3 and Stat-1, -3, -4, and -5B. Conversely, in
the glomerular compartment, Jak/Stat pathway members
were mainly increased in early diabetic nephropathy com-
pared with control subjects then downregulated in pro-
gressive diabetic nephropathy (Fig. 1, lower panel).
Real-time RT-PCR analysis of RNA from control and
early and progressive diabetic nephropathy micro-
dissected biopsies was performed to conﬁrm the mRNA
changes of Jak/Stat pathway members. As suggested by
the microarray data, a signiﬁcant regulation of Jak-1, -2,
and -3 and Stat-1 and -3 mRNAs was demonstrated in
glomeruli from patients with early and progressive dia-
betic nephropathy and in the tubulointerstitium of patients
with progressive diabetic nephropathy. In contrast to the
microarray data, real-time RT-PCR found that mRNA ex-
pression of most Jak/Stat family members remained ele-
vated in glomeruli from progressive diabetic nephropathy
patients compared with control samples (Supplementary
Table 5A). In the remainder of our study, we focused on
Jak-2 since it appears to play a key role in proinﬂammatory
responses in both glomerular and tubular cells (24). Jak-2
mRNA levels were signiﬁcantly increased in the glomeruli
of early diabetic nephropathy patients and in the tubulo-
interstitium of patients with progressive diabetic nephrop-
athy compared with those of control subjects (Fig. 2A).
Jak-2 mRNA levels were not increased in glomeruli or
tubulointerstitium from patients with other progressive
kidney diseases (Supplementary Table 5B).
The estimated GFR (eGFR) of patients with diabetic
nephropathy (early and progressive), as calculated by the
Modiﬁcation of Diet in Renal Disease Study formula (25),
was strongly and inversely correlated with Jak-2 tubuloin-
terstitial (Fig. 2B) but not glomerular mRNA levels, as
determined by quantitative RT-PCR; this is also true with
1/serum creatinine (Supplementary Table 5C). Tubuloin-
terstitial, but not glomerular, mRNA expression of Jak-1
and -3 and Stat-1 were also inversely and signiﬁcantly
correlated with eGFR and 1/serum creatinine (Supplemen-
tary Table 5C). Mean blood pressure also inversely corre-
lated with tubulointerstitial Jak-3 mRNA expression
(Supplementary Table 5C).
Jak-2 immunohistochemistry showed a robust increase
in Jak-2 protein expression in proximal tubular epithelia
and glomerular cells in diabetic nephropathy compared
with those in control subjects and other progressive
kidney diseases (Fig. 2C), indicating that protein expres-
sion corresponded with mRNA levels. In the tubulointer-
stitial regions, contribution from cellular elements other
than tubular cells was minimal (data not shown).
Jak-2 expression in db/db C57BLKS and STZ-induced
DBA/2J diabetic mice. Since common murine diabetic
nephropathy models fail to develop severe glomeruloscle-
rosis or tubulointerstitial ﬁbrosis and kidney failure, we
hypothesized that these models would also fail to manifest
critical gene expression changes that occur in humans
with progressive diabetic nephropathy. Db/db C57BLKS
mice and STZ-induced diabetic DBA/2J mice develop
robust changes of early diabetic nephropathy (albumin-
uria, mesangial expansion, and podocyte loss) but do not
develop the signiﬁcant tubulointerstitial ﬁbrosis and de-
cline in kidney function that characterize progressive
diabetic nephropathy in humans (10,23,24). Therefore, we
speciﬁcally hypothesized that Jak-2 expression would be
unchanged in the glomeruli and renal cortex (largely
tubulointerstitial tissue) of these two mouse models. In-
deed, Jak-2 mRNA and protein levels were similar in
diabetic mice and their nondiabetic controls (Fig. 3).
Effects of increased Jak-2 expression in murine mes-
angial cells. To determine whether increases in Jak-2
expression alone could induce downstream signaling, we
analyzed the overexpression of Jak-2 in cultured mouse
mesangial cells for 36 h. Jak-2 overexpression in cells
incubated in normal (5.5 mmol/l) glucose resulted in a
threefold increase in phosphorylation of Stat-3 on tyrosine
705, consistent with Stat-3 activation (Fig. 4). There was
no signiﬁcant change in the level of total Stat-3 protein.
Incubation in high (30 mmol/l) glucose medium alone did
not signiﬁcantly enhance Stat-3 phosphorylation com-
pared with normal (5.5 mmol/l glucose) but did lead to an
additive increase in Stat-3 phosphorylation in the Jak-2–
transfected cells. We also determined whether increased
Jak-2 expression could enhance ROS species, since en-
hanced ROS generation appears to be a hallmark of
progressive diabetic nephropathy in humans (26). As de-
termined by CM-H2DCF ﬂuorescence, a signiﬁcant in-
crease in ROS was observed in Jak-2–overexpressing cells
compared with control vector cells when both cell types
were grown in 5.5 mmol/l glucose (Fig. 5). A similar
increase in ROS generation was demonstrated in control
vector cells incubated in 30 mmol/l glucose media com-
pared with cells grown in 5.5 mmol/l glucose median.
There was a further, but nonsigniﬁcant, increase in ROS in
Jak-2–transfected cells incubated in high glucose medium
compared with Jak-2–transfected cells grown in normal
glucose medium.
DISCUSSION
Diabetic nephropathy in humans requires activation of
multiple molecular programs to become manifest. The
current pathophysiological understanding of diabetic ne-
phropathy is derived largely from analysis of animal and
cellular models. Several pathways were identiﬁed by these
approaches and were conﬁrmed to play critical roles in the
evolution of diabetic nephropathy in humans (27,28).
However, despite pathogenic changes in a variety of
different signaling pathways, current murine models of
diabetic nephropathy fail to completely replicate progres-
sive human diabetic nephropathy (glomerulosclerosis, tu-
bulointerstitital ﬁbrosis, and decline in GFR) (10). This
discrepancy could be due to partial, incomplete, or tem-
porary activation of critical pathogenic responses and/or
distinctive protective responses that counteract or prevent
nephropathy in mice that are not manifest in humans. To
identify those human-speciﬁc pathogenic or murine pro-
tective pathways, we used a comparative transcriptomic
approach to study diabetic nephropathy in both species.
In human diabetes, as assessed by microarray analysis
and conﬁrmed by RT-PCR and immunohistochemistry, the
Jak/Stat signaling pathway appeared to be one of the top
regulated pathways and was consistently altered in both
glomeruli and tubulointerstitium from patients with dia-
betic nephropathy. Marrero’s group previously has identi-
ﬁed Jak/Stat activation as potentially pathogenic in
mediating angiotenisin II signaling, in inducing trans-
forming growth factor- expression, and in stimulating
extracellular matrix protein production in cultured mes-
angial cells and animal models of diabetic nephropathy
(14,15,24,29,30). However, to our knowledge the current
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472 DIABETES, VOL. 58, FEBRUARY 2009report is the ﬁrst study to demonstrate enhanced Jak/Stat
expression in human diabetic nephropathy. While multiple
members of the Jak/Stat family showed increased mRNA
expression in microarrays and RT-PCR expression studies,
we focused on the expression patterns of Jak-2, since it is
a critical upstream regulator of many Jak/Stat signaling
events and was already implicated in processes that en-
hance ﬁbrosis and epithelial mesenchymal transition in
diabetic nephropathy (11,13–15,24,29,30).
Our ﬁndings suggest an interesting compartmental and
temporal association of enhanced Jak-2 expression. Glo-
merular Jak-2 mRNA levels increase several-fold in dia-
betic patients with early diabetic nephropathy and then
decline in later stages as tubulointerstitial Jak-2 increases
along with progressive tubulointerstitial ﬁbrosis and re-
duction in kidney function. Thus, enhanced Jak-2 expres-
sion temporally corresponds to the evolution of human
diabetic nephropathy, with glomerulopathy followed by
B
0
20
40
60
80
100
120
140
0.0 0.3 0.5 0.8 1.0 1.3 1.5
R2 = 0.440
p = 0.0006
Jak2/18S rRNA
Early DN
Progressive DN
Tubulointerstitium compartment
0.0
0.2
0.4
0.6
0.8
1.0
1.2 p = 0.019
n.s.
n=9 n=11 n=12
J
a
k
2
/
1
8
S
 
r
R
N
A
A
Glomerular compartment
0.0
2.0
4.0
6.0
8.0
10.0
n=6 n=12 n=10
p = 0.006
n.s.
J
a
k
2
/
1
8
S
 
r
R
N
A
G
F
R
-
M
D
R
D
 
[
m
l
.
m
i
n
.
1
.
7
3
m
2
]
C
Control
Control
Prog. DN (case 1)
Prog. DN (case 1)
Prog. DN (case 2)
Prog. DN (case 2)
M
a
g
n
i
f
i
c
a
t
i
o
n
:
 
1
0
0
X
M
a
g
n
i
f
i
c
a
t
i
o
n
:
 
4
0
0
X
LN
LN HTN
IgAN
IgAN
M
a
g
n
i
f
i
c
a
t
i
o
n
:
 
1
0
0
X
M
a
g
n
i
f
i
c
a
t
i
o
n
:
 
4
0
0
X
HTN
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mRNA expression (as measured by real-time RT-PCR) with eGFR in patients with early (, n  11) and progressive (F, n  12) diabetic
nephropathy. C: Representative Jak-2 immunohistographs of kidney biopsies from patients with no kidney disease (Control), progressive
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DIABETES, VOL. 58, FEBRUARY 2009 473tubulointerstitial ﬁbrosis. The impressive inverse correla-
tion between tubulointerstitial with eGFR suggests a po-
tential causal relationship between enhanced Jak/Stat
expression and progressive tubulointerstitial ﬁbrosis and
renal failure. While some of this apparent correlation
could be due to population differences between the early
diabetic nephropathy group, who are all Pima Indians, and
the mostly European progressive diabetic nephropathy
group, a strong correlation between tubulointerstitial
Jak-2 expression and eGFR remained in the progressive
diabetic nephropathy group alone, suggesting that this
association was not due to population differences.
Jak-2 mRNA induction in diabetic nephropathy was
conﬁrmed by immunochemistry and appears to be diabetic
nephropathy speciﬁc, as there was no induction of Jak-2
mRNA in glomeruli or tubulointerstitum in lupus nephritis,
IgA nephropathy, or hypertensive nephrosclerosis. Jak-2
protein expression was increased in both glomeruli and
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thy, but there was variable expression in other nephropa-
thies with tubular damage and proteinuria, consistent with
the notion that Jak-2 activation is not generic to all
progressive renal diseases. This observation conﬁrmed the
results obtained by Affymetrix GeneChip compared with
those for control patients (living donors, n  21), where
Jak-2 mRNA showed no consistent regulation in patients
with hypertensive nephropathy (n  20), IgA nephropathy
(n  27), and lupus nephritis (n  32), with fold changes
between 0.93 and 1.10 in the glomerular and tubulointer-
stitial compartments.
Similarly, there was no correlation between gene ex-
pression of Jak-2 or other Jak/Stat members in diabetic
nephropathy samples with blood pressure, duration of
diabetes, glycosylated hemoglobin, or BMI (with the sole
exception of Jak-3 and blood pressure), suggesting that
the correlation with eGFR was speciﬁc and not due to
some confounding factor. Nonetheless, a signiﬁcant cor-
relation between Jak-2 and eGFR does not necessarily
imply a causal connection between the two parameters,
nor does it imply directionality if a causal relationship
exists. It is imperative to follow up these studies with
prospective analysis of patients with diabetic nephropathy
to determine whether glomerular or tubulointerstitial
Jak-2 expression truly predicts progression of diabetic
nephropathy in humans. Additionally, tissue-speciﬁc Jak-2–
overexpression studies in animal models of diabetic ne-
phropathy will be important.
The absence of enhanced Jak-2 expression in the db/db
C57BLKS and STZ-induced diabetic DBA/2J mouse dia-
betic nephropathy models is interesting since these mod-
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(10,22,31,32), develop high levels of albuminuria and un-
dergo extensive early glomerular changes of diabetic
nephropathy (22,31,32) but rarely progress to severe glo-
merulosclerosis and do not develop signiﬁcant tubuloin-
terstitial ﬁbrosis and progressive kidney failure (10,31,32).
No increases in Jak-2 mRNA or protein expression were
found in either glomerular or tubulointerstitial compart-
ments, suggesting one possible reason for the lack of
progressive diabetic nephropathy induction in these
mouse models. It is certainly likely that additional re-
sponses critical for progression of human diabetic ne-
phropathy are missing in conventional murine models of
diabetic nephropathy and that protective responses in
mouse models may be absent from humans with progres-
sive diabetic nephropathy. Thus, the strategy of uncover-
ing divergent responses between human progressive
diabetic nephropathy and murine models of early diabetic
nephropathy may reveal other pathways that are essential
for the pathogenesis of diabetic nephropathy and that are
potential targets for therapeutic or prevention strategies.
Since Jak/Stat pathways are activated by growth factors,
cytokines, or other upstream signals, and because Jak-2
protein activation is via autophosphorylation, enhanced
Jak-2 expression should result in Stat tyrosine phosphor-
ylation and activation only with Jak-2 activation. Thus, it
was important to test whether Jak-2 overexpression alone
could induce Stat phosphorylation and other downstream
responses. While in vivo conﬁrmation of such a response
necessarily awaits the generation and testing of tissue-
speciﬁc Jak-2 transgenic mice, we have conﬁrmed that
Jak-2 overexpression alone, without additional growth
factors or cytokines, substantially increases Stat-3 phos-
phorylation on tyrosine 705. This observation conﬁrms
activation of Jak-2/Stat-3 signaling simply by overexpress-
ing Jak-2 in mouse mesangial cells. Interestingly, high
glucose had only a modest and statistically insigniﬁcant
effect on Stat-3 phosphorylation, implying that high glu-
cose alone is not sufﬁcient to trigger Jak-2 signaling in our
system. However, high glucose had an additive effect on
Jak-2 overexpression on Stat-3 phosphorylation. The mo-
lecular mechanism by which Jak-2 overexpression induces
Stat-3 phosphorylation remains to be determined.
Enhanced production of ROS has been described as a
potential major activator of Jak/Stat signaling (33) and can
occur independently of the addition of exogenous cyto-
kines (34). This phenomenon appears to be relatively
general since ROS mediate induction of Jak-2 activation in
tissues such as cardiac myocytes and vascular smooth
muscle cells (34–36) as well as kidney cells (12,14,15,32).
We did not test whether ROS could further augment the
signaling to Stat-3 in our Jak-2–overexpressing cells but
we did show that Jak-2 overexpression induced ROS
production in mesangial cells, especially those cultured in
high glucose medium. This observation suggests the pres-
ence of an ampliﬁcation loop in diabetic glomerular and
proximal tubular cells in which there is both enhanced
Jak-2 expression, as shown in this study, as well as
enhanced ROS production, due to metabolic alterations
resulting from enhanced glucose ﬂux (26,37). These two
independent processes can each enhance the other, lead-
ing to progressive downstream signaling from both path-
ways and inexorable ﬁbrosis and kidney failure.
Enhanced Jak-2 expression in both glomerular and
proximal tubule cells may stimulate a host of downstream
processes that lead to the glomerulosclerosis, tubulointer-
stitial ﬁbrosis, and kidney failure that affects up to 40% of
diabetic patients. The absence of this response may pro-
tect mice from these late, but deadly, aspects of progres-
sive diabetic nephropathy. Further exploration of Jak/Stat
pathways in diabetic nephropathy as well as additional
systems analysis of the differences between mice and
humans may elucidate targets for therapies that could help
humans with diabetic nephropathy be more like mice.
ACKNOWLEDGMENTS
These studies were supported in part by grants from the
National Institute of Diabetes and Digestive and Kidney
Diseases (U01 DK60994 to F.C.B., U01 DK076139 to F.C.B.
and M.K., and R21 DK079441 to M.K.) and the Intramural
Research Program of the National Institute of Diabetes
and Digestive and Kidney Diseases. This research used the
Morphology and Image Analysis Core of the Michigan
Diabetes Research and Training Center supported by
National Institutes of Health Grant DK20572.
No potential conﬂicts of interest relevant to this article
were reported.
We are indebted to Drs. Almut Nitsche and Bodo
Brunner (sanoﬁ-aventis Deutschland, Frankfurt, Germany)
for DNA chip hybridizations and delivery of the dataset of
hybridization results.
APPENDIX
Members of the European Renal cDNA Bank-Kroener-
Fresenius biopsy bank at the time of the study: C.D.
Cohen, M. Fischereder, H. Schmid, P.J. Nelson, M. Kret-
zler, D. Schloendorff, Munich; J.D. Sraer, P. Ronco, Paris;
M.P. Rastaldi, G. D’Amico, Milan; F. Mampaso, Madrid; P.
Doran, H.R. Brady, Dublin; D. Moenks, Goettingen; P.
Mertens, J. Floege, Aachen; N. Braun, T. Risler, Tuebingen;
L. Gesualdo, F.P. Schena, Bari; J. Gerth, G. Wolf, Jena; R.
Oberbauer, D. Kerjaschki, Vienna; B. Banas, B.K. Kraemer,
Regensburg; W. Samtleben, Munich; H. Peters, H.H. Neu-
mayer, Berlin; K. Ivens, B. Grabensee, Dueseldorf; R.P.
Wuethrich, Zurich; V. Tesar, Prague.
REFERENCES
1. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC:
Structural-functional relationships in diabetic nephropathy. J Clin Invest
74:1143–1155, 1984
2. Mauer SM, Lane P, Zhu D, Fioretto P, Steffes MW: Renal structure and
function in insulin-dependent diabetes mellitus in man. J Hypertens Suppl
10:S17–20, 1992
3. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM: Glomerular
lesions and urinary albumin excretion in type I diabetes without overt
proteinuria. N Engl J Med 320:966–970, 1989
4. Nangaku M: Mechanisms of tubulointerstitial injury in the kidney: ﬁnal
common pathways to end-stage renal failure. J Int Med 43:9–17, 2004
5. Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A:
Structure and function of the kidney in diabetic glomerulosclerosis:
correlations between morphological and functional parameters. Pathol
Res Pract 167:204–216, 1980
6. Fioretto P, Mauer M: Histopathology of diabetic nephropathy. Semin
Nephrol 27:195–207, 2007
7. Henger A, Kretzler M, Doran P, Bonrouhi M, Schmid H, Kiss E, Cohen CD,
Madden S, Porubsky S, Grone EF, Schlondorff D, Nelson PJ, Grone HJ:
Gene expression ﬁngerprints in human tubulointerstitial inﬂammation and
ﬁbrosis as prognostic markers of disease progression. Kidney Int 65:904–
917, 2004
8. Kretzler M, Cohen CD, Doran P, Henger A, Madden S, Grone EF, Nelson PJ,
Schlondorff D, Grone HJ: Repuncturing the renal biopsy: strategies for
molecular diagnosis in nephrology. J Am Soc Nephrol 13:1961–1972, 2002
9. Susztak K, Bottinger EP: Diabetic nephropathy: a frontier for personalized
medicine. J Am Soc Nephrol 17:361–367, 2006
10. Breyer MD, Boettinger E, Brosius FC, Coffman TM, Harris RC, Heilig CW,
JAK/STAT AND DIABETIC NEPHROPATHY
476 DIABETES, VOL. 58, FEBRUARY 2009Sharma K: AMDCC: mouse models of diabetic nephropathy. JA mS o c
Nephrol 16:27–45, 2005
11. Huang JS, Chuang LY, Guh JY, Chen CJ, Yang YL, Chiang TA, Hung MY,
Liao TN: Effect of nitric oxide-cGMP-dependent protein kinase activation
on advanced glycation end-product-induced proliferation in renal ﬁbro-
blasts. J Am Soc Nephrol 16:2318–2329, 2005
12. Nakajima H, Takenaka M, Kaimori JY, Hamano T, Iwatani H, Sugaya T, Ito
T, Hori M, Imai E: Activation of the signal transducer and activator of
transcription signaling pathway in renal proximal tubular cells by albumin.
J Am Soc Nephrol 15:276–285, 2004
13. Nightingale J, Patel S, Suzuki N, Buxton R, Takagi KI, Suzuki J, Sumi Y,
Imaizumi A, Mason RM, Zhang Z: Oncostatin M, a cytokine released by
activated mononuclear cells, induces epithelial cell-myoﬁbroblast transdif-
ferentiation via Jak/Stat pathway activation. J Am Soc Nephrol 15:21–32,
2004
14. Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, Marrero MB:
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK
and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal
Physiol 286:F653–F659, 2004
15. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB: Inhibition of the
Jak/STAT signaling pathway prevents the high glucose-induced increase in
TGF- and ﬁbronectin synthesis in mesangial cells. Diabetes 51:3505–3509,
2002
16. Cohen CD, Frach K, Schlondorff D, Kretzler M: Quantitative gene expres-
sion analysis in renal biopsies: a novel protocol for a high-throughput
multicenter application. Kidney Int 61:133–140, 2002
17. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A,
Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlondorff D,
Cohen CD: Interstitial vascular rarefaction and reduced VEGF-A expres-
sion in human diabetic nephropathy. J Am Soc Nephrol 18:1765–1776, 2007
18. Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F,
Nitsche A, Kiss E, Bleich M, Grone HJ, Nelson PJ, Schlondorff D, Cohen
CD, Kretzler M: European Renal c DNABC: modular activation of nuclear
factor-kappaB transcriptional programs in human diabetic nephropathy.
Diabetes 55:2993–3003, 2006
19. Lorz C, Benito-Martin A, Boucherot A, Ucero AC, Rastaldi MP, Henger A,
Armelloni S, Santamaria B, Berthier CC, Kretzler M, Egido J, Ortiz A: The
death ligand TRAIL in diabetic nephropathy. J Am Soc Nephrol 19:904–914,
2008
20. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC III: Reduction in
podocyte density as a pathologic feature in early diabetic nephropathy in
rodents: prevention by lipoic acid treatment. BMC Nephrol 7:6, 2006
21. Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, Kretzler M,
Feldman EL, Pennathur S, Brosius 3rd FC: Rosiglitazone reduces renal and
plasma markers of oxidative injury and reverses urinary metabolite
abnormalities in the amelioration of diabetic nephropathy. Am J Physiol
Renal Physiol 295:F1071–F1081, 2008
22. Sharma K, McCue P, Dunn SR: Diabetic kidney disease in the db/db mouse.
Am J Physiol Renal Physiol 284:F1138–F1144, 2003
23. Argetsinger LS, Kouadio JL, Steen H, Stensballe A, Jensen ON, Carter-Su C:
Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its
activity. Mol Cell Biol 24:4955–4967, 2004
24. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC: Role of the JAK/
STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal
Physiol 290:F762–F768, 2006
25. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker
G: Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW,
Striker G: The effects of dietary protein restriction and blood-pressure
control on the progression of chronic renal disease: Modiﬁcation of Diet in
Renal Disease Study Group. N Engl J Med 330:877–884, 1994
26. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS,
Mauer M: Susceptibility to diabetic nephropathy is related to dicarbonyl
and oxidative stress. Diabetes 54:3274–3281, 2005
27. Brosius FC, Heilig CW: Glucose transporters in diabetic nephropathy.
Pediatr Nephrol 20:447–451, 2005
28. Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephrop-
athy and vascular complications: protein kinase C beta inhibition. Am J
Kidney Dis 42:456–465, 2003
29. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB:
Angiotensin II activation of the JAK/STAT pathway in mesangial cells is
altered by high glucose. Kidney Int 61:1605–1616, 2002
30. Banes-Berceli AK, Shaw S, Ma G, Brands M, Eaton DC, Stern DM, Fulton
D, Caldwell RW, Marrero MB: Effect of simvastatin on high glucose- and
angiotensin II-induced activation of the JAK/STAT pathway in mesangial
cells. Am J Physiol Renal Physiol 291:F116–F121, 2006
31. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD: Character-
ization of susceptibility of inbred mouse strains to diabetic nephropathy.
Diabetes 54:2628–2637, 2005
32. Gurley SB, Clare SE, Snow KP, Hu A, Meyer TW, Coffman TM: Impact of
genetic background on nephropaty in diabetic mice. Am J Physiol Renal
Physiol 290:F214–F222, 2006
33. Simon AR, Rai U, Fanburg BL, Cochran BH: Activation of the JAK-STAT
pathway by reactive oxygen species. Am J Physiol 275:C1640–C1652, 1998
34. Madamanchi NR, Moon SK, Hakim ZS, Clark S, Mehrizi A, Patterson C,
Runge MS: Differential activation of mitogenic signaling pathways in aortic
smooth muscle cells deﬁcient in superoxide dismutase isoforms. Arterio-
scler Thromb Vasc Biol 25:950–956, 2005
35. Modesti A, Bertolozzi I, Gamberi T, Marchetta M, Lumachi C, Coppo M,
Moroni F, Toscano T, Lucchese G, Gensini GF, Modesti PA: Hyperglycemia
activates JAK2 signaling pathway in human failing myocytes via angioten-
sin II-mediated oxidative stress. Diabetes 54:394–401, 2005
36. Madamanchi NR, Li S, Patterson C, Runge MS: Reactive oxygen species
regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler
Throm Vasc Biol 21:321–326, 2001
37. Brownlee M: Biochemistry and molecular cell biology of diabetic compli-
cations. Nature 414:813–820, 2001
C.C. BERTHIER AND ASSOCIATES
DIABETES, VOL. 58, FEBRUARY 2009 477